Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
BMJ. 2024 Jun 5:385:q1237.
doi: 10.1136/bmj.q1237.